Bai, J., Asakawa, T., Yuan, W., Lin, Y., Ju, H., Xu, D., . . . Zhang, X. Efficacy and safety of SHEN26, a novel oral small molecular RdRp inhibitor for COVID-19 treatment: A multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial. BMC.
Chicago Style (17th ed.) CitationBai, Jiangtao, et al. Efficacy and Safety of SHEN26, a Novel Oral Small Molecular RdRp Inhibitor for COVID-19 Treatment: A Multicenter, Randomized, Double-blinded, Placebo-controlled, Phase II Clinical Trial. BMC.
MLA (9th ed.) CitationBai, Jiangtao, et al. Efficacy and Safety of SHEN26, a Novel Oral Small Molecular RdRp Inhibitor for COVID-19 Treatment: A Multicenter, Randomized, Double-blinded, Placebo-controlled, Phase II Clinical Trial. BMC.
Warning: These citations may not always be 100% accurate.